Lucie Ellis-Taitt
Articles
-
Nov 7, 2024 |
insights.citeline.com | Lucie Ellis-Taitt
In Vivo’s Deals Of The Year: Cast Your Vote!It is time for In Vivo's 16th annual Deals of the Year contest. We've selected 12 nominees across three categories – Top M&A, Top Alliance and Top Financing – and you get to pick the winners.
-
Nov 6, 2024 |
insights.citeline.com | Lucie Ellis-Taitt
Seres Names Kurt Graves To Board Seres Therapeutics, a microbiome therapeutics platform company, has appointed Kurt Graves to its board of directors. Graves, the chair, president and CEO of Intarcia Therapeutics, brings to Seres extensive experience from his 25-year career at top-tier pharmaceutical and biotech companies.
-
Oct 21, 2024 |
insights.citeline.com | Lucie Ellis-Taitt
GSK Spotlights Three Impending Drug Launches In 3Q UpdateGlaxoSmithKline focused on three upcoming launches for its pharmaceutical business during its Q3 update, during which CEO Emma Walmsley also speculated briefly about acquiring Pfizer's consumer health business. GSK 3Q Update: focus falls on new product launches • Source: Shutterstock
-
Oct 16, 2024 |
insights.citeline.com | Lucie Ellis-Taitt
Regeneron Aiming To Be A Cell And Gene Medicine ‘Powerhouse’Increased R&D spending, program acquisitions and a soaring headcount – Regeneron has seen significant growth over the past 5 years. The company is focused on marrying its antibody technologies with its expanding cell and gene therapy pipeline.
-
Oct 16, 2024 |
insights.citeline.com | Lucie Ellis-Taitt
J.P. Morgan Highlights: Major M&A Missing, But Key Takeaways For Year AheadThe annual J.P. Morgan Health Care Conference has come to a close. In Vivo has summarized some of the key themes to appear from 2022’s meeting of industry leaders, investors and technology creators. Bolt-on deals in focus for pharma in 2022 • Source: Alamy
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →